<DOC>
	<DOCNO>NCT01355913</DOCNO>
	<brief_summary>In myelodysplastic syndrome ( MDS ) knowledge chromosomal aberration important diagnosis , pathogenesis , prognosis treatment . Usually , chromosomal anomaly MDS patient detect bone marrow cell chromosome band analysis metaphase . Alternatively additionally diagnose Fluorescence-in-Situ-Hybridization ( FISH ) . The investigator present novel method cytogenetic monitoring MDS patient peripheral blood representative clone size bone marrow cell . The purpose prospective multicenter non-interventional diagnostic study detect follow chromosomal aberration peripheral blood closely , assess karyotype evolution , detect rare abnormality correlate molecular-cytogenetic result peripheral blood count , bone marrow morphology treatment modality response .</brief_summary>
	<brief_title>Screening Genetic Monitoring Patients With Myelodysplastic Syndromes ( MDS ) Under Different Treatment Modalities Cytogenetic Analyses Circulating CD34+Cells</brief_title>
	<detailed_description>Chromosomal aberration myelodysplastic syndrome ( MDS ) play major role diagnostics , pathogenesis , prognosis , , recently , treatment allocation . Chromosomal anomaly detect conventional chromosome banding analyse bone marrow metaphases provable Fluorescence situ hybridization ( FISH ) circulate CD34+ progenitor cell peripheral blood . For prospective multicenter non-interventional diagnostic study sequential FISH analysis perform immunomagnetically enrich circulate CD34+ cell peripheral blood follow : A `` super-panel '' probe D7/CEP7 , EGR1 , CEP8 , CEP XY , D20 , p53 , IGH/BCL2 , TEL/AML1 , RB1 , MLL , 1p36/1q25 , CSF1R ( AbbottÂ® probe ) use initial screening , every 12 month follow-up every case suspect progression . A small `` standard-panel '' probe EGR1 , D7/CEP7 , CEP8 , p53 , D20 , CEP X/Y , TEL/AML1 - plus necessary informative probe superpanel- perform analysis short interval every 2 month 1st year every 3 month 2nd 3rd year . Peripheral blood count document month , full blood count number peripheral blast recommend time point FISH analysis . Bone marrow biopsy part study , recommend perform every 6 12 month course disease . If bone marrow biopsy perform , conventional chromosome banding analyse bone marrow metaphase , additionally , FISH analyse enrich CD34+ bone marrow cell non-enriched bone marrow cell perform . The result peripheral blood correlate conventional banding FISH analyse perform bone marrow sample . The aim study detect acqired chromosomal aberration MDS patient peripheral blood , follow anomaly frequent analysis , detect rare aberration observe karyotype evolution peripheral blood .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Clinical diagnosis ( cytomorphologic proof ) primary secondary myelodysplastic syndrome ( MDS ) Suspected myelodysplastic syndrome ( MDS ) . Age &gt; 18 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Myelodysplastic syndrome ( MDS )</keyword>
	<keyword>chromosmal aberration</keyword>
	<keyword>cytogenetics</keyword>
	<keyword>Fluorescence situ hybridization ( FISH )</keyword>
	<keyword>CD34+ cell</keyword>
	<keyword>peripheral blood</keyword>
</DOC>